New Data from New York Medical College Illuminate Research in Parkinson's Disease (Beta [ [2] ] -Adrenergic Suppression of Neuroinflammation in Treatment of Parkinsonism, with Relevance for Neurodegenerative and Neoplastic Disorders).

A new report from New York Medical College discusses the potential therapeutic value of beta-adrenergic agonists in Parkinson's disease. These agents may suppress the formation of a-synuclein protein, which is associated with the development of Lewy bodies. The study focuses on the role of the prototypical beta-adrenergic agonist epinephrine and its synthetic selective receptor agonist levalbuterol in suppressing neuroinflammation and degeneration of dopaminergic neurons. The findings suggest that these agents may have implications for the treatment of Parkinson's disease, other neurodegenerative syndromes, and malignancies. [Extracted from the article]